PT1162993E - Utilizacao de polipeptidos casb616 e polinucleotidos para o tratamento de cancro - Google Patents

Utilizacao de polipeptidos casb616 e polinucleotidos para o tratamento de cancro

Info

Publication number
PT1162993E
PT1162993E PT00907633T PT00907633T PT1162993E PT 1162993 E PT1162993 E PT 1162993E PT 00907633 T PT00907633 T PT 00907633T PT 00907633 T PT00907633 T PT 00907633T PT 1162993 E PT1162993 E PT 1162993E
Authority
PT
Portugal
Prior art keywords
casb616
polypeptides
treatment
polynucleotid
cancer
Prior art date
Application number
PT00907633T
Other languages
English (en)
Inventor
Bassols Carlota Vinals Y De
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PT1162993E publication Critical patent/PT1162993E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Catalysts (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
PT00907633T 1999-03-05 2000-02-28 Utilizacao de polipeptidos casb616 e polinucleotidos para o tratamento de cancro PT1162993E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9905124.5A GB9905124D0 (en) 1999-03-05 1999-03-05 Novel compounds

Publications (1)

Publication Number Publication Date
PT1162993E true PT1162993E (pt) 2005-06-30

Family

ID=10849064

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00907633T PT1162993E (pt) 1999-03-05 2000-02-28 Utilizacao de polipeptidos casb616 e polinucleotidos para o tratamento de cancro

Country Status (23)

Country Link
US (1) US20050129717A1 (pt)
EP (2) EP1466616A3 (pt)
JP (1) JP2002538218A (pt)
KR (1) KR20010102507A (pt)
CN (1) CN1374869A (pt)
AT (1) ATE292472T1 (pt)
AU (1) AU766789B2 (pt)
BR (1) BR0008784A (pt)
CA (1) CA2362370A1 (pt)
CY (1) CY1105585T1 (pt)
CZ (1) CZ20013189A3 (pt)
DE (1) DE60019273T2 (pt)
ES (1) ES2238026T3 (pt)
GB (1) GB9905124D0 (pt)
HK (1) HK1043729B (pt)
HU (1) HUP0200186A2 (pt)
IL (1) IL145046A0 (pt)
NO (1) NO20014292L (pt)
NZ (1) NZ513837A (pt)
PL (1) PL354143A1 (pt)
PT (1) PT1162993E (pt)
TR (1) TR200102577T2 (pt)
WO (1) WO2000053216A2 (pt)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774223B2 (en) * 2000-06-28 2004-08-10 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
PT2266603E (pt) * 2000-10-18 2012-11-02 Glaxosmithkline Biolog Sa Vacinas tumorais
CN1446583A (zh) * 2002-11-29 2003-10-08 帕弗瑞生物技术(北京)有限公司 一种肿瘤免疫治疗及预防性疫苗的组成、制备、应用方案
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
IN2012DN03025A (pt) 2009-09-09 2015-07-31 Ct Se Llc
PE20130342A1 (es) 2010-04-15 2013-04-20 Spirogen Sarl Pirrolobenzodiacepinas y conjugados de las mismas
RU2626537C2 (ru) 2010-06-08 2017-07-28 Дженентек, Инк. Полученные с помощью генной инженерии антитела с цистеиновыми заменами и их конъюгаты
ES2544608T3 (es) 2010-11-17 2015-09-02 Genentech, Inc. Conjugados de anticuerpo y de alaninil-maitansinol
WO2012155019A1 (en) 2011-05-12 2012-11-15 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
EP2750713B1 (en) 2011-10-14 2015-09-16 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
CN105102068B (zh) 2012-10-12 2018-06-01 Adc疗法责任有限公司 吡咯并苯并二氮杂卓-抗体结合物
MX364329B (es) 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina.
KR101819404B1 (ko) 2012-10-12 2018-02-28 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
ES2660029T3 (es) 2012-10-12 2018-03-20 Medimmune Limited Conjugados de anticuerpo-pirrolobenzodiazepinas
PL2906253T3 (pl) 2012-10-12 2019-02-28 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina-przeciwciało anty-psma
EP2906250B1 (en) 2012-10-12 2018-05-30 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-psma antibody conjugates
AU2013328628B2 (en) 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
CN110452242A (zh) 2012-12-21 2019-11-15 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
CA2894959C (en) 2012-12-21 2022-01-11 Spirogen Sarl Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
BR112015023070B1 (pt) 2013-03-13 2022-06-07 Genentech, Inc. Conjugados e compostos de pirrolobenzodiazepinas, composição farmacêutica que compreende os mesmo, bem como seus usos para o tratamento de uma doença proliferativa
KR102066318B1 (ko) 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
BR112016002829A2 (pt) 2013-08-12 2017-09-19 Genentech Inc Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
KR20160092024A (ko) 2013-12-16 2016-08-03 제넨테크, 인크. 1-(클로로메틸)-2,3-디히드로-1H-벤조[e]인돌 이량체 항체-약물 접합체 화합물, 및 사용 및 치료 방법
MX371092B (es) 2013-12-16 2020-01-16 Genentech Inc Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos.
EA201691023A1 (ru) 2013-12-16 2016-10-31 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
KR20170052600A (ko) 2014-09-12 2017-05-12 제넨테크, 인크. 시스테인 가공된 항체 및 콘주게이트
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
AU2015317653A1 (en) 2014-09-17 2017-04-06 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
CN107206101B (zh) 2014-12-03 2021-06-25 基因泰克公司 季铵化合物及其抗体-药物缀合物
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP6943872B2 (ja) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
PL3544636T3 (pl) 2017-02-08 2021-12-06 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina-przeciwciało
RS63502B1 (sr) 2017-04-18 2022-09-30 Medimmune Ltd Konjugati pirolobenzodiazepina
CA3057748A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
US11318211B2 (en) 2017-06-14 2022-05-03 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
NZ761175A (en) 2017-08-18 2024-07-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
TW201920192A (zh) 2017-09-20 2019-06-01 韓商Ｐｈ製藥公司 泰蘭他汀（ｔｈａｉｌａｎｓｔａｔｉｎ）類似物
US11068545B2 (en) 2017-11-17 2021-07-20 Battelle Memorial Institute Spatial identification of assets using n-dimensional asset identifiers
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
WO2020086858A1 (en) 2018-10-24 2020-04-30 Genentech, Inc. Conjugated chemical inducers of degradation and methods of use
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU766077C (en) * 1998-11-20 2004-10-07 Genentech Inc. Uses for Eph receptor antagonists and agonists to treat vascular disorders

Also Published As

Publication number Publication date
PL354143A1 (en) 2003-12-29
AU766789B2 (en) 2003-10-23
CZ20013189A3 (cs) 2002-02-13
ATE292472T1 (de) 2005-04-15
EP1162993A2 (en) 2001-12-19
GB9905124D0 (en) 1999-04-28
BR0008784A (pt) 2001-12-26
WO2000053216A3 (en) 2001-01-11
JP2002538218A (ja) 2002-11-12
AU2915300A (en) 2000-09-28
NO20014292L (no) 2001-10-29
DE60019273D1 (de) 2005-05-12
TR200102577T2 (tr) 2004-09-21
NZ513837A (en) 2003-02-28
HK1043729B (zh) 2005-11-04
CN1374869A (zh) 2002-10-16
DE60019273T2 (de) 2006-01-19
ES2238026T3 (es) 2005-08-16
EP1162993B1 (en) 2005-04-06
NO20014292D0 (no) 2001-09-04
EP1466616A3 (en) 2004-12-01
CA2362370A1 (en) 2000-09-14
KR20010102507A (ko) 2001-11-15
CY1105585T1 (el) 2010-07-28
WO2000053216A2 (en) 2000-09-14
HK1043729A1 (en) 2002-09-27
US20050129717A1 (en) 2005-06-16
HUP0200186A2 (en) 2002-05-29
IL145046A0 (en) 2002-06-30
EP1466616A2 (en) 2004-10-13

Similar Documents

Publication Publication Date Title
PT1162993E (pt) Utilizacao de polipeptidos casb616 e polinucleotidos para o tratamento de cancro
CY2008007I1 (el) Χρηση του et743 στην συνδυαστικη θεραπεια με δεξαμεθαζονη για την θεραπευτικη αγωγη του καρκινου
EP1311262A4 (en) COMBINED TREATMENT AGAINST CANCER
IL164599A0 (en) Combination therapy for the treatment of cancer
HK1080840A1 (en) Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and the use thereof for treating benign and malignant tumour diseases
CY1111147T1 (el) Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου
ZA200205191B (en) LIV-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer.
HUP0500424A3 (en) Combination therapy for the treatment of cancer
HUP0300054A1 (hu) Daganatspecifikus állati fehérjék
IL145047A0 (en) Casb618 polynucleotides and polypeptides and their use
MXPA03003032A (es) Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos.
BR0009358A (pt) Compostos
ZA200203166B (en) Treatment of cancer.
ZA200107282B (en) Use of CASB616 polypeptides and polynucleotides for cancer treatment.
WO2000043509A3 (en) Polynucleotides and their applications in diagnostics
GB2397018B (en) Combination therapy for treating disease
WO2001023417A3 (en) Human tumor-associated lak-4p related polynucleotides and polypeptides and their uses
ZA200408071B (en) Combination therapy for the treatment of cancer.
SI1162993T1 (en) Use of casb616 polypeptides and polynucleotides for cancer treatment
GB9826888D0 (en) Cervical cancer treatment